ALNY

Alnylam Pharmaceuticals
D

ALNY

219.830
USD
-11.35
(-4.91%)
Post Trading·220.370USD+0.540(+0.25%)
Volume
84,505
EPS
9
Div Yield
-
P/E
38
Market Cap
29,415,258,410
Overview
Related Instruments
AMGN
AMGN
D
Amgen
403.02
-4.34(-1.07%)
402.56-0.46(-0.11%)
ARWR
ARWR
D
Arrowhead Pharmaceuticals
64.170
-0.605(-0.93%)
C
CRSP
D
CRISPR Therapeutics AG
55.440
0.010(0.02%)
55.260-0.180(-0.32%)
GILD
GILD
D
Gilead Sciences
144.700
-2.800(-1.90%)
144.840+0.140(+0.10%)
IONS
IONS
D
Ionis Pharmaceuticals
43.520
-0.460(-1.05%)
43.790+0.270(+0.62%)
MRNA
MRNA
D
Moderna
189.990
0.970(0.51%)
189.600-0.390(-0.21%)
REGN
REGN
D
Regeneron Pharmaceuticals
735.64
0.99(0.13%)
VRTX
VRTX
D
Vertex Pharmaceuticals
504.62
-1.94(-0.38%)
More
Articles
ALNY article featured image

What Is the DAX and How to Invest in It?

Learn what the DAX index is, how it works, which companies it includes, and how you can invest or trade it. A practical guide for retail investors and traders.

1 month ago
Trading Beginners
More

Title: Alnylam Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercialRNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Smarter Decisions,Together
FacebookTwitterYoutubeLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.